Combination of IAP antagonist and IFNγ activates novel caspase-10-and RIPK1-dependent cell death pathways

48Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

Abstract

Peptido-mimetic inhibitor of apoptosis protein (IAP) antagonists (Smac mimetics (SMs)) can kill tumour cells by depleting endogenous IAPs and thereby inducing tumour necrosis factor (TNF) production. We found that interferon-γ (IFNγ) synergises with SMs to kill cancer cells independently of TNF-and other cell death receptor signalling pathways. Surprisingly, CRISPR/Cas9 HT29 cells doubly deficient for caspase-8 and the necroptotic pathway mediators RIPK3 or MLKL were still sensitive to IFNγ/SM-induced killing. Triple CRISPR/Cas9-knockout HT29 cells lacking caspase-10 in addition to caspase-8 and RIPK3 or MLKL were resistant to IFNγ/SM killing. Caspase-8 and RIPK1 deficiency was, however, sufficient to protect cells from IFNγ/SM-induced cell death, implying a role for RIPK1 in the activation of caspase-10. These data show that RIPK1 and caspase-10 mediate cell death in HT29 cells when caspase-8-mediated apoptosis and necroptosis are blocked and help to clarify how SMs operate as chemotherapeutic agents.

Cite

CITATION STYLE

APA

Tanzer, M. C., Khan, N., Rickard, J. A., Etemadi, N., Lalaoui, N., Spall, S. K., … Silke, J. (2017). Combination of IAP antagonist and IFNγ activates novel caspase-10-and RIPK1-dependent cell death pathways. Cell Death and Differentiation, 24(3), 481–491. https://doi.org/10.1038/cdd.2016.147

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free